On March 1 and 2, 2018, the National Institutes of Health 2018 Progenitor Cell Translational Consortium, Cardiovascular Bioengineering Symposium, was held at the University of Alabama at Birmingham. Convergence of life sciences and engineering to advance the understanding and treatment of heart failure was the theme of the meeting. Over 150 attendees were present, and >40 scientists presented their latest work on engineering human functional myocardium for disease modeling, drug development, and heart failure research. The scientists, engineers, and physicians in the field of cardiovascular sciences met and discussed the most recent advances in their work and proposed future strategies for overcoming the major roadblocks of cardiovascular bioengineering and therapy. Particular emphasis was given for manipulation and using of stem/progenitor cells, biomaterials, and methods to provide molecular, chemical, and mechanical cues to cells to influence their identity and fate in vitro and in vivo. Collectively, these works are profoundly impacting and progressing toward deciphering the mechanisms and developing novel treatments for left ventricular dysfunction of failing hearts. Here, we present some important perspectives that emerged from this meeting.
Bibliographical noteFunding Information:
The authors gratefully acknowledge the National Institutes of Health (NIH) support of their research, NIH UO1 HL134764, the Progenitor Cell Biology Consortium (grant HL099997), and the Symposium held at University of Alabama-Birmingham in March 2018. This work was a product of discussions at the NIH Progenitor Cell Translational Consortium Cardiovascular Bioengineering Symposium, March 2018.
© 2018 American Heart Association, Inc.
- heart failure
- stem cells
- tissue engineering